These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7389058)

  • 1. Low-dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer. A randomized clinical study.
    Bolis G; Bortolozzi G; Carinelli G; D'Incalci M; Gramellini F; Morasca L; Mangioni C
    Cancer Chemother Pharmacol; 1980; 4(2):129-32. PubMed ID: 7389058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. cis-Platinum, adriamycin, and hexamethylmelamine versus cyclophosphamide in advanced ovarian carcinoma.
    Carmo-Pereira J; Costa FO; Henriques E
    Cancer Chemother Pharmacol; 1983; 10(2):100-3. PubMed ID: 6403254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: a randomized clinical trial.
    Sessa C; Bolis G; Colombo N; D'Incalci M; Mermillod B; Valente I; Mangioni C
    Cancer Chemother Pharmacol; 1985; 14(3):222-8. PubMed ID: 3922639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination chemotherapy with adriamycin-cyclophosphamide for advanced ovarian carcinoma.
    Parker LM; Griffiths CT; Yankee RA; Canellos GP; Gelman R; Knapp RC; Richman CM; Tobias JS; Weiner RS; Frei E
    Cancer; 1980 Aug; 46(4):669-74. PubMed ID: 7397632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. cis-Dichlorodiammineplatinum(II) alone followed by adriamycin plus cyclophosphamide at progression versus cis-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide in combination for adenocarcinoma of the lung.
    Britell JC; Eagan RT; Ingle JN; Creagen ET; Rubin J; Frytak S
    Cancer Treat Rep; 1978 Aug; 62(8):1207-10. PubMed ID: 688256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma.
    Omura GA; Morrow CP; Blessing JA; Miller A; Buchsbaum HJ; Homesley HD; Leone L
    Cancer; 1983 Mar; 51(5):783-9. PubMed ID: 6401594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin (P) versus cyclophosphamide, adriamycin and cisplatin (CAP) for stage III-IV epithelial ovarian carcinoma: a prospective randomized trial.
    Tomirotti M; Perrone S; Giè P; Canaletti R; Carpi A; Biasoli R; Lombardi F; Giovanninetti A; Mensi F; Villa S
    Tumori; 1988 Oct; 74(5):573-7. PubMed ID: 3217992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of cyclophosphamide plus cisplatin versus hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin in combination as initial chemotherapy for stage III and IV ovarian carcinomas.
    Edmonson JH; McCormack GW; Fleming TR; Cullinan SA; Krook JE; Malkasian GD; Podratz KC; Mailliard JA; Jefferies JA; Barlow JF
    Cancer Treat Rep; 1985 Nov; 69(11):1243-8. PubMed ID: 3937598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hexamethylmelamine in ovarian cancer resistant to cyclophosphamide and adriamycin.
    Bolis G; D'Incalci M; Belloni C; Mangioni C
    Cancer Treat Rep; 1979 Aug; 63(8):1375-7. PubMed ID: 113096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adriamycin, BCNU, and cyclophosphamide in drug-resistant adenocarcinoma of the ovary.
    Presant CA; Bartolucci A
    Med Pediatr Oncol; 1983; 11(3):151-3. PubMed ID: 6682929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy for advanced ovarian cancer: a prospective randomized trial comparing hexamethylmelamine and cyclophosphamide to doxorubicin and cyclophosphamide.
    Schwartz PE; Lawrence R; Katz M
    Cancer Treat Rep; 1981; 65(1-2):137-41. PubMed ID: 6261948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of 96-hr continuous-infusion etoposide and doxorubicin with bolus cyclophosphamide in refractory epithelial ovarian cancer.
    Fleming GF; Waggoner SE; Rotmensch J; Skoog LA; Langhauser C
    Gynecol Oncol; 1997 Apr; 65(1):42-5. PubMed ID: 9103389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adriamycin in combination for the treatment of breast cancer: a Southwest Oncology Group study.
    Tranum B; Hoogstraten B; Kennedy A; Vaughn CB; Samal B; Thigpen T; Rivkin S; Smith F; Palmer RL; Costanzi J; Tucker WG; Wilson H; Maloney TR
    Cancer; 1978 Jun; 41(6):2078-83. PubMed ID: 657081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
    Conte PF; Bruzzone M; Chiara S; Sertoli MR; Daga MG; Rubagotti A; Conio A; Ruvolo M; Rosso R; Santi L
    J Clin Oncol; 1986 Jun; 4(6):965-71. PubMed ID: 3519886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer: a randomized trial.
    Chlebowski RT; Hestorff R; Sardoff L; Weiner J; Bateman JR
    Cancer; 1978 Dec; 42(6):2546-52. PubMed ID: 365313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of a Southwest Oncology Group phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer.
    Hannigan EV; Green S; Alberts DS; O'Toole R; Surwit E
    Oncology; 1993 Nov; 50 Suppl 2():2-9. PubMed ID: 8233297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adriamycin and Cytoxan in the treatment of inoperable lung cancer.
    Hoeltgen TM; MacIntyre JM; Perlia CP; Lagakos SW; Stolbach LL; Bennett JM
    Cancer; 1983 Jun; 51(11):2005-12. PubMed ID: 6301671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the therapeutic effects of adriamycin alone versus adriamycin plus vincristine versus adriamycin plus cyclophosphamide in the treatment of advanced carcinoma of the cervix.
    Wallace HJ; Hreshchyshyn MM; Wilbanks GD; Boronow RC; Fowler WC; Blessing JA
    Cancer Treat Rep; 1978 Oct; 62(10):1435-41. PubMed ID: 709549
    [No Abstract]   [Full Text] [Related]  

  • 19. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.
    Gadducci A; Carnino F; Chiara S; Brunetti I; Tanganelli L; Romanini A; Bruzzone M; Conte PF
    Gynecol Oncol; 2000 Feb; 76(2):157-62. PubMed ID: 10637064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized study comparing carboplatin/cyclophosphamide and cisplatin/cyclophosphamide as first-line treatment in patients with stage III/IV epithelial ovarian cancer and small volume disease. German Ovarian Cancer Study Group (GOCA).
    Meerpohl HG; Sauerbrei W; Kühnle H; Schumacher M; Pfleiderer A
    Gynecol Oncol; 1997 Jul; 66(1):75-84. PubMed ID: 9234925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.